Transactions
8
Insider / Merck & Co., Inc.
DeLuca Richard R.
EVP&Pres, Merck Animal Heallth at Merck & Co., Inc. · MRK
DeLuca Richard R., EVP&Pres, Merck Animal Heallth at Merck & Co., Inc., has disclosed 8 transactions in MRK since August 10, 2026: 0 purchases (0 open-market buys) and 8 sales, worth about $6.7M at the reported prices. The latest was filed August 12, 2026, 0 days after the trade.
Open-market buys
0
Sales
8
Avg. disclosure lag
2.0d
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source |
|---|---|---|---|---|---|---|---|---|---|
| MRK | Sell S | August 12, 2026 | August 12, 2026 | 0d | 600 | $132 | $79K | Form 4 ↗ | |
| MRK | Sell S | August 12, 2026 | August 12, 2026 | 0d | 11,099 | $132 | $1.5M | Form 4 ↗ | |
| MRK | Sell S | August 11, 2026 | August 12, 2026 | 1d | 5,427 | $132 | $718K | Form 4 ↗ | |
| MRK | Sell S | August 11, 2026 | August 12, 2026 | 1d | 7,410 | $131 | $973K | Form 4 ↗ | |
| MRK | Sell S | August 10, 2026 | August 12, 2026 | 2d | 20,784 | $130 | $2.7M | Form 4 ↗ | |
| MRK | Sell S | August 6, 2026 | August 10, 2026 | 4d | 300 | $131 | $39K | Form 4 ↗ | |
| MRK | Sell S | August 6, 2026 | August 10, 2026 | 4d | 4,945 | $130 | $644K | Form 4 ↗ | |
| MRK | Sell S | August 6, 2026 | August 10, 2026 | 4d | 805 | $131 | $105K | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| August 12, 2026 | Form 4 | 0000310158-26-000219 | 5 | published | EDGAR ↗ |
| August 10, 2026 | Form 4 | 0000310158-26-000217 | 3 | published | EDGAR ↗ |
Sources and method
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.